Female sexual dysfunction: anatomy of a diagnosis
Disease mongering is the practice of widening the boundaries of illness, or promoting awareness of a condition, in ways that expand the market for treatment, often by presenting normal experiences or mild difficulties as medical disorders in need of a product. The construction of female sexual dysfunction is one of the most closely studied examples of that process, and it is also a case that demands care, because sexual distress and dissatisfaction are common and genuinely painful for many people. The debate is not about whether such distress is real. It is about how a broad, memorable diagnosis and a market to match were assembled around it.
What disease mongering means
The medical journalist Lynn Payer gave the phrase its currency in her 1992 book on how the widening of illness boundaries can be used to sell treatments. Later writers, including Ray Moynihan and Alan Cassels in their book on the marketing of illness and the contributors to the 2006 PLoS Medicine collection on the subject, refined it into a set of recognizable tactics. In plain terms, disease mongering means turning the ordinary ups and downs of life, or ordinary risk, into diagnosable conditions. It is a descriptive term for a pattern in health marketing, not an accusation against any individual, and identifying it in a given case does not prove bad faith so much as describe how research, advocacy, medicine, and the pharmaceutical industry can align to expand a diagnosis.
A useful working definition has three parts: a condition is defined or broadened; its frequency is presented as high and underrecognized; and treatments, usually a drug, are promoted as the answer. Female sexual dysfunction became a prominent example because researchers were able to document all three parts as they happened.
How female sexual dysfunction was constructed
Female sexual dysfunction, often abbreviated FSD, is an umbrella term covering difficulties with desire, arousal, orgasm, and pain. The clinical categories behind it, including the diagnosis once called hypoactive sexual desire disorder, are set out in psychiatric and medical classification systems and have been revised repeatedly. That revision history is part of the story: the way the categories are drawn, combined, and named has changed over time, which is a sign that the boundary is a matter of expert judgment rather than a fixed biological fact.
In a widely cited 2003 analysis in the BMJ, the journalist and researcher Ray Moynihan examined what he called the making of the disease. He described how a corporate-sponsored process of definition, involving meetings that brought together researchers and pharmaceutical-industry interests, helped shape a broad diagnostic category, and how that category was accompanied by striking prevalence claims. The most famous figure, drawn from a 1999 survey published in a leading American medical journal, reported that a large proportion of women had experienced some sexual problem. Critics argued that a finding about common, often transient difficulties was being repackaged as evidence that a widespread medical dysfunction was going untreated. Supporters of the research countered that sexual problems were genuinely underdiscussed and that naming them could reduce shame and prompt care.
Disease mongering and drug marketing
The commercial engine behind the FSD debate was the search for a pharmaceutical treatment. After the commercial success of erectile-difficulty drugs in men, there was strong interest in finding an equivalent product for women, and the existence of a large, well-defined patient population would make any such drug far more valuable. This is the point at which defining the condition and building the market become hard to separate.
The later approval of flibanserin, marketed as Addyi, for low sexual desire in some women crystallized the argument. Its approval in the United States followed a campaign that framed the issue partly as one of equality, arguing that women lacked treatments that men had. Critics, including many clinicians and some women’s-health advocates, questioned the drug’s modest measured benefit against its side effects and objected to a condition being promoted alongside its remedy. Defenders argued that women with genuine, distressing loss of desire deserved options and that dismissing the diagnosis risked dismissing their suffering. Both positions can be stated fairly, and the disagreement among reasonable experts is itself part of what makes this a landmark case.
The pattern that critics identify in the marketing runs as follows:
- A broad diagnostic category is defined that groups mild and severe difficulties together.
- Prevalence figures suggest the problem is extremely common and largely untreated.
- Awareness efforts and advertising raise the profile of both the condition and a treatment, so that the availability of a drug becomes part of the case that the disorder is widespread.
Why this case is contested, not closed
Female sexual dysfunction remains genuinely debated, and honesty requires presenting more than one view. On one side, scholars who study medicalization argue that a spectrum of ordinary and situational sexual experience, influenced by relationships, stress, life stage, and circumstance, was compressed into a single medical dysfunction with a convenient treatment. On the other side, sexual-medicine clinicians argue that some women experience persistent, distressing problems that are real, treatable, and too often ignored, and that having recognized diagnoses helps those women get care rather than being told their difficulties are trivial.
Both things can be true at once. A real spectrum of distress exists, and the specific boundaries, prevalence claims, and marketing around FSD were commercially shaped. Recognizing the second does not deny the first. The consistent message of this reference applies here with particular force: the experiences are real, and nothing on this page tells any reader whether a diagnosis applies to them or what to do about it. What the case study examines is narrower and public: how a name, a boundary, and a market were built around human experience, and why careful observers still disagree about where recognition ends and disease mongering begins.